

Abstract Volume

60th EASD Annual Meeting
9 - 13 September 2024
Madrid, Spain





60th EASD Annual Meeting of the European Association for the Study of Diabetes

Madrid, Spain, 9 - 13 September 2024

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024

Abstracts

Index of Oral Presentations

- OP 01 New mechanisms and outcomes of treatments for diabetic kidney disease
- OP 02 Which day of the week is your insulin day?
- OP 03 Liver: the master regulator
- OP 04 Beyond glucose in diabetes and prediabetes
- OP 05 Can you change what you are by what you eat?
- OP 06 Maternal influences and prediction in type 1 diabetes
- OP 07 Cardiovascular complications in type 1 diabetes: burden and mechanisms
- OP 08 Genetics and epigenetics in type 2 diabetes
- OP 09 Drugs you thought you knew all about, but what else do they do?
- OP 10 Hypothalamic regulation of systems metabolism
- OP 11 Risk factors and treatment opportunities in neuropathy and hypertension
- OP 12 Fatal attraction: immune cells and beta cells
- OP 13 GLP-1-based polypharmacology: we are not done yet!
- OP 14 Incretins: How many targets do you need?
- OP 15 Cardiovascular risk in patients with type 1 diabetes: What do we know today, how can we modify it tomorrow?
- OP 16 Emerging risk factors and treatment options for diabetic eye disease
- OP 17 Type 2 diabetes prediction
- OP 18 How to blow the low
- OP 19 Prediction and prognosis of type 1 diabetes
- OP 20 Are you afrAID?
- OP 21 Cardiovascular risk in diabetes: in search of the holy grail
- OP 22 Actions of incretins on the brain and pancreas you might not know about
- OP 23 Why exercise?
- OP 24 Islets forever: survival of the beta cells
- OP 25 Incretin receptor agonists: better and better
- OP 26 Love goes through the stomach: new roles for GLP-1
- OP 27 Predictors of diabetic kidney disease progression from omics to ethnicity
- OP 28 New kids on the block: stem cell islets
- OP 29 More on hormones
- OP 30 Causes and consequences of gestational diabetes
- OP 31 Macrovascular outcomes of diabetes: a holistic view
- OP 32 Fine tuning CGMing
- OP 33 Emerging science in diabetic kidney disease from fasting to autophagy

- OP 34 [B]reaking [F]at
- OP 35 Insulin: ready, steady, go!
- OP 36 Inside information on beta cell regulation
- OP 37 Protection in islet transplantation
- OP 38 New insights into CNS regulation of energy and glucose metabolism
- OP 39 Novel insights in monogenic diabetes
- OP 40 Around liver fat: the fight is on
- OP 41 Turning back the biological clock - or merely slowing it?
- OP 42 New factors in the control of glucose tolerance
- OP 43 Treating type 1 diabetes: What else does the future hold?
- OP 44 The unforgettable alpha cells
- OP 45 How smart an insulin pen can be?
- OP 46 Pregnancy: taking care of the future
- OP 47 Inflammatory mechanisms regulating systems metabolism
- OP 48 Managing diabetic foot disease: clinical studies and omics predictors

Index of Short Oral Discussions

- SO 001 Genetic insights into type 2 diabetes: from risk variants to personalized treatment strategies
- SO 002 Epigenetics and gestational diabetes: from maternal health to newborn outcomes
- SO 003 The many facets of weight and type 2 diabetes risk
- SO 004 Diet, lifestyle, and metabolic health: insights into diabetes risk and prevention
- SO 005 Unraveling monogenic diabetes: from genetic variants to innovative diagnostic tools
- SO 006 Advancements in predicting type 1 diabetes
- SO 007 Global perspectives on type 2 diabetes: prevalence, risk factors, and predictive tools
- SO 008 Advances type 1 diabetes: genetic, biomarker, and machine learning approaches
- SO 009 Treatment of type 1 diabetes
- SO 010 Complications of type 1 diabetes
- SO 011 Disease progression and mortality in diabetes
- SO 012 Health interactions and risks in diabetes: from cancer survival to chronic conditions
- SO 013 Prevention of type 2 diabetes
- SO 014 Early factors and family determinants of diabetes
- SO 015 Genetics and biomarkers for prediction of type 2 diabetes
- SO 016 Molecular predictors of type 1 diabetes
- SO 017 Long-term complications and outcomes in type 2 diabetes: vascular health, kidney function, and mortality

- SO 018 Diabetes management and outcomes: societal, behavioral, and clinical influences
- SO 019 Catching signals to follow the right pathway in islets
- SO 020 Holding hands with alpha cells in the islets
- SO 021 Insulin service providers for the body
- SO 022 Cells in attacking mode and beta cell victims
- SO 023 Keeping islet cell identity under different circumstances
- SO 024 Improving islet transplantation
- SO 025 Breaking bad: destruction of beta cells
- SO 026 Pregnancy and type 1 diabetes
- SO 027 Gestational diabetes: clinical perspective
- SO 028 Biomarkers and mechanisms in gestational diabetes
- SO 029 On the young ones...
- SO 030 Investigating impact of gestational diabetes
- SO 031 All the reasons why exercise is good!
- SO 032 Insulin action in peripheral tissues
- SO 033 Understanding insulin sensitivity: What can we learn from human studies?
- SO 034 Novel mechanisms of insulin resistance
- SO 035 Non-insulin hormones
- SO 036 Keeping your beta cells alive
- SO 037 New approaches in carbohydrate metabolism
- SO 038 Novel pharmacological approaches for the treatment of obesity and diabetes
- SO 039 Improving metabolic outcome by bariatric surgery
- SO 040 Now the brown fat talks
- SO 041 Towards a better understanding of the adipose tissue - liver axis
- SO 042 How lifestyle affects our health
- SO 043 Inflammation and beta cell homeostasis
- SO 044 Lipid signatures and ectopic fat
- SO 045 Preclinical advances to better understand energy, glucose and lipid metabolism
- SO 046 What's new on white fat function?
- SO 047 Novel mechanisms regulating energy and glucose metabolism
- SO 048 Novel mechanisms controlling glucometabolic health
- SO 049 Novel clinical insights into adipose tissue function
- SO 050 Understanding and combating adipose tissue dysfunction
- SO 051 Metabolic alterations in obesity and diabetes-linked co-morbidities
- SO 052 Preclinical advances to understand glucose metabolism
- SO 053 Oral agents to control glucose metabolism
- SO 054 Improving metabolism via the gut
- SO 055 Improving metabolism through nutrition
- SO 056 Thinking outside the box to treat obesity and diabetes
- SO 057 Novel therapeutic avenues for metabolic disease
- SO 058 SGLT2 inhibition: focus on the heart and the kidneys
- SO 059 Pleiotropic effects of SGLT2 inhibition
- SO 060 Novel incretins: it is all about clinical outcomes
- SO 061 Novel incretins: focus on kidney, liver and cardiovascular system
- SO 062 Hot of the press novel incretins
- SO 063 More combo's less insulin!
- SO 064 Incretins have more effects than you can imagine
- SO 065 Advanced real life in type 1 diabetes
- SO 066 Pumping without bumping
- SO 067 Breaking away with tradition or how to give insulin differently
- SO 068 Playing with food intake and energy expenditure
- SO 069 HbA1c vs CGM: a tie break?
- SO 070 De-combining CGM and insulin in type 2 diabetes
- SO 071 How universal can CGM be?
- SO 072 The future of diabetes science is here
- SO 073 Diabetes technology - but at a higher level
- SO 074 It is very hard to beat the system - or is it?
- SO 075 A lesson in diabetes geography
- SO 076 Up or down and back
- SO 077 Continuous monitoring of CGM
- SO 078 More stress on distress
- SO 079 From microbiology to MRI in diabetic foot disease
- SO 080 Diabetic kidney disease: clinical insights from childhood to frailty
- SO 081 Advances in diabetic kidney disease from cells to histology
- SO 082 Predicting and treating renal complications. What's new in 2024?
- SO 083 The four M's of microvascular complications: MRI, Mitochondria, Models, and iMaging
- SO 084 Mechanisms and treatment for microvascular complications: nerves, eyes, and blood vessels
- SO 085 Clinical data and emerging markers in diabetic foot disease and neuropathy
- SO 086 Novel markers and predictors for neuropathy in diabetes
- SO 087 Clinical studies on the crosstalk between neuropathy and other systems
- SO 088 Fatty liver in diabetes: pathways and relationships
- SO 089 Brain matters in diabetes
- SO 090 Skeletal muscles and subcutaneous adipose tissue: important players in diabetes management
- SO 091 A new look at well-known drugs in type 2 diabetes
- SO 092 Divination from a glass ball or something more? Predictive models, biomarkers, genome analysis
- SO 093 A non-classical look at type 1 diabetes
- SO 094 Cohorts, trials and cardiovascular disease
- SO 095 Other complications of type 2 diabetes
- SO 096 A non-traditional look at type 2 diabetes
- SO 097 Pathogenesis of diabetes complications
- SO 098 Cancer and diabetes
- SO 099 A non-traditional look at type 1 diabetes
- SO 100 Correlates of fatty liver disease in diabetes
- SO 101 MASLD: now an established complication of diabetes
- SO 102 Addressing risk and consequences of liver pathology in diabetes

Late-breaking Abstracts

Index of LBA Oral Presentations

- LBA OP 01 Advancements in diabetes management and cardiovascular health
- LBA OP 02 Exercise, metabolism and hormonal responses in diabetes
- LBA OP 03 Incretin-based therapies and metabolic insights in diabetes
- LBA OP 04 Diabetes management: protecting kidney function and preventing retinopathy
- LBA OP 05 Diabetes, mental health and neuroprotection: emerging evidence and mechanisms
- LBA OP 06 Transformative islet therapies and genetic discoveries
- LBA OP 07 Emerging technologies in diabetes: from closed loop systems to non-invasive screening

Index of LBA Short Oral Discussions

- LBA SO 01 Ailing heart, broken vessels
- LBA SO 02 How NOT to get from fat to sweet
- LBA SO 03 One size down, three (or more) to go
- LBA SO 04 Never leave the liver (especially the fatty one)!
- LBA SO 05 Incretins up and roaring

Disclosure: **S.K. Hecquet:** None.

SO 088 Fatty liver in diabetes: pathways and relationships

946

Vitamin D₃ in the regulation of autophagy and mitochondrial dynamics in non-alcoholic fatty liver disease induced by type 2 diabetes

O. Lisakovska¹, A. Khomenko¹, O. Mezhenska¹, T. Horid'ko², T. Kuchmerovska¹, M. Veliky¹, I. Shymanskyi¹;

¹Department of Biochemistry of Vitamins and Coenzymes, Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine, ²Department of Lipids Biochemistry, Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine.

Background and aims: Autophagy disorder, characterized by impaired intracellular self-degradation, has been reportedly implicated in various pathologies, including non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). Vitamin D₃ (D₃) and D₃ receptor (VDR) may play a hepatoprotective role by inhibiting oxidative stress, inflammation and fibrosis. However, whether D₃-VDR pathway regulates abnormal autophagy in NAFLD remains unclear. Herein, our goal was to elucidate the relationship between autophagy disorder and D₃ status, hepatic expression of VDR and D₃-metabolizing enzymes, as well as oxidative stress in T2DM-induced NAFLD.

Materials and methods: We induced T2DM in male Wistar rats using a high-fat diet (3 months) and a low dose of streptozotocin (25 mg/kg of body weight). Diabetic rats were treated with or without D₃ (1000 IU/kg b.w., 30 days). Hepatosteatosis was assayed by staining with Sudan III&Gill's Hematoxylin II and AFOG. ELISA was used to measure 25-hydroxyvitamin D₃ (25D₃). Target proteins were determined in liver tissue by Western blotting. Data were analyzed by one-way ANOVA followed by *Tukey's* test and $p < 0.05$ was considered to be statistically significant.

Results: Liver examination revealed steatosis without signs of inflammatory tissue destruction and fibrosis in T2DM. Diabetes lowered circulating 25D₃ (2.8-fold) and downregulated hepatocellular protein levels of vitamin D₃-25-hydroxylase (CYP27A1, CYP2R1), 25OHD₃-1 α -hydroxylase (CYP27B1), and VDR in diabetic vs. control rats. A 2.9- and 1.7-fold elevation of carbonylated and nitrated (3-nitrotyrosin) proteins was shown in diabetic liver vs. control ($p < 0.05$). Hepatic levels of ATG7 and the molecular chaperone Hsp70 increased by 1.4 and 4.2 times, respectively, with the simultaneous 3.1-fold decrease in cathepsin B and unchanged levels of cathepsin L and calpain-2 in T2DM vs. control ($p < 0.05$), indicative of T2DM-related activation of autophagy. In addition, we detected an increase in molecular markers of both mitochondrial fusion (mitofusins 1 and 2 - by 1.7- and 4.2-fold, respectively) and mitochondrial fission (Fis1 - by 5.0-fold) vs. control ($p < 0.05$), suggesting a significant enhancement of mitochondrial dynamics in T2DM. Repletion of 25D₃ following vitamin D₃ treatment upregulated the expression of VDR and D₃-metabolizing enzymes and diminished the content of carbonylated and nitrated proteins in the liver. D₃ contributed to partial or complete normalization of the content of autophagy proteins except for calpain-2. Notably, D₃ shifted the balance between mitochondrial fission/fusion towards fission, as it inhibited the expression of mitofusins 1 and 2 and significantly stimulated Fis1 synthesis.

Conclusion: We identified an association between T2DM-induced D₃ deficiency, increased oxidative-nitrosative stress, and autophagy in liver tissue that correlated with enhanced mitochondrial dynamics as a possible mechanism of bioenergetic adaptation to the metabolic demands of cells. The therapeutic efficacy of vitamin D₃ in alleviating diabetic NAFLD was demonstrated.

Supported by: This work was funded by the National Research Foundation of Ukraine (grant 2021.01/0417)

Disclosure: **O. Lisakovska:** None.

947

One-hour plasma glucose concentration during the OGTT is a strong predictor of hepatic steatosis in nondiabetic individuals

F. Al-Mulla¹, M. Abu-Farha², F. Alajmi³, J. Abubaker³, M. Ahmed⁴, M. Qaddoumi⁵, M. Shehab⁶, A. John Mclaws⁷, T. Alessa³, A. Alhubail⁸, D. Alsaed², M. Arouj², A. Bennakhi³, R. DeFronzo⁹, M. Abdulghani³;

¹Genetics & Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, Kuwait, ²Dasman Diabetes Institute, Kuwait City, Kuwait, ³Translational Research Department, Dasman Diabetes Institute, Kuwait City, Kuwait, ⁴Dasman Diabetes Institute, Kuwait, Kuwait, ⁵Biochemistry and Molecular Biology department, Dasman Diabetes Institute, Kuwait City, Kuwait, ⁶University San Antonio Texas, San Antonio, TX, USA, ⁷Clinical Laboratory, Dasman Diabetes Institute, Kuwait City, Kuwait, ⁸UTHSCSA, San Antonio, TX, USA.

Background and aims: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is intricately linked with Type 2 Diabetes Mellitus (T2DM), transitioning to more severe conditions in a subset of patients. Despite its relatively benign nature, MAFLD can progress to Metabolic Associated Steatohepatitis (MASH) and chronic liver disease. With a notable prevalence among T2DM and prediabetes patients, the predictive capability of 1-hour plasma glucose (1-h PG) levels during an Oral Glucose Tolerance Test (OGTT) for MAFLD risk in nondiabetic individuals is of significant interest. This study aims to investigate the predictive value of 1-h PG for MAFLD amongst individuals without diabetes.

Materials and methods: We conducted a study involving 300 non-diabetic participants who underwent a 75-gram OGTT and liver fat assessment through elastography. Participants were categorized into normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and undiagnosed diabetes based on the American Diabetes Association criteria.

Results: The study cohort comprised 148 NGT, 43 IFG, 74 IGT, and 35 undiagnosed diabetes participants. Liver fat, as measured by Controlled Attenuation Parameter (CAP) score, showed a significant increase across the spectrum from NGT (232 \pm 4), IFG (253 \pm 7), IGT (266 \pm 6), to undiagnosed diabetes (292 \pm 9; $p < 0.0001$). The 1-h PG level was significantly correlated with the CAP score ($r = 0.41$, $p < 0.01$), demonstrating superior predictive power over traditional indices of hepatic steatosis. A 1-h PG > 155 mg/dl identified NGT and IFG subjects with a high risk of elevated CAP scores, indicative of significant liver fat accumulation comparable to IGT subjects. The proportion of NGT and IFG subjects with advanced steatosis (Stage S3/4) was notably higher in those with 1-h PG > 155 mg/dl compared to their counterparts with lower 1-h PG levels.

Conclusion: The 1-hour plasma glucose level during an OGTT is a significant indicator of liver fat content in nondiabetic individuals, revealing an elevated risk for future T2DM and MAFLD in subjects with 1-h PG > 155 mg/dl. These findings highlight the potential of 1-h PG as an early predictive marker for MAFLD, advocating for its consideration in preventive strategies against the progression of MAFLD and its associated complications.

Clinical Trial Registration Number: NCT06115876

Supported by: Kuwait Foundation for the advancement of Sciences

Disclosure: **F. Al-Mulla:** None.

948

Machine learning approach reveals proteome and lipidome profile in patients with metabolic associated fatty liver disease complicated with poly-vascular plaques

Z. Tu, T. Yue, Y. Ding, X. Zheng, S. Luo, J. Weng;